---
document_datetime: 2025-01-07 12:18:53
document_pages: 6
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/evkeeza-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: evkeeza-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 3.7962505
conversion_datetime: 2025-12-30 20:45:37.517842
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## EVKEEZA

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                             |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|---------------------------------------------------------------------|
| II/0015              | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one       | 14/11/2024                          | 13/12/2024                                  | SmPC, Annex II and PL            | Please refer to Scientific Discussion 'Evkeeza-H-C-005449- II-0015' |
| IB/0020              | B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process | 27/11/2024                          | n/a                                         |                                  |                                                                     |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| S/0018              | Annual re-assessment.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 19/09/2024   | n/a        |    | The CHMP, having reviewed the evidence of compliance with the specific obligations and the impact of the data submitted by the MAH on the benefit/risk profile of the medicinal product, concluded that marketing authorisation of EVKEEZA should be maintained.   |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10945 /202402 | Periodic Safety Update EU Single assessment - evinacumab                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 05/09/2024   | n/a        |    | PRAC Recommendation - maintenance                                                                                                                                                                                                                                  |
| N/0019              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 24/07/2024   | 13/12/2024 | PL |                                                                                                                                                                                                                                                                    |
| IAIN/0017/G         | This was an application for a group of variations. B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of | 04/06/2024   | n/a        |    |                                                                                                                                                                                                                                                                    |
| PSUSA/10945 /202308 | Periodic Safety Update EU Single assessment - evinacumab                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 07/03/2024   | n/a        |    | PRAC Recommendation - maintenance                                                                                                                                                                                                                                  |

<div style=\"page-break-after: always\"></div>

| II/0011   | Extension of indication to include the treatment of paediatric patients with homozygous familial hypercholesterolaemia (HoFH) aged 5 years and older for EVKEEZA, based on interim results from study R1500-CL-17100, as well as supportive information from an updated interim analysis of study R1500-CL-1719, and an extrapolation analysis (including population PK, population PK/PD, and simulation analyses). R1500-CL-17100 is an ongoing multicentre, three-part, single-arm, open-label study evaluating the efficacy, safety, and tolerability of evinacumab in paediatric patients aged â‰¥5 to 11 years with HoFH. As a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. The Annex II and the Package Leaflet are updated in accordance. Version 1.2 of the RMP has also been submitted. In addition, the marketing authorisation holder took the opportunity to introduce minor editorial changes to the PI. Furthermore, the PI is brought in line with the latest QRD template version 10.3. C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or   | 09/11/2023   | 11/12/2023   | SmPC, Annex II and PL   | Please refer to Scientific Discussion 'EMEA-H-C-005449-II- 0011'   |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|-------------------------|--------------------------------------------------------------------|
| IB/0014   | B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 30/11/2023   | n/a          |                         |                                                                    |

<div style=\"page-break-after: always\"></div>

| IB/0012/G           | This was an application for a group of variations. B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.5.a - Change to in-process tests or limits applied during the manufacture of the finished   | 09/11/2023   | n/a        |                       |                                                                                                                                                                                                                                                                  |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10945 /202302 | Periodic Safety Update EU Single assessment - evinacumab                                                                                                                                                                                                                                   | 28/09/2023   | n/a        |                       | PRAC Recommendation - maintenance                                                                                                                                                                                                                                |
| S/0010              | Annual re-assessment.                                                                                                                                                                                                                                                                      | 14/09/2023   | n/a        |                       | The CHMP, having reviewed the evidence of compliance with the specific obligations and the impact of the data submitted by the MAH on the benefit/risk profile of the medicinal product, concluded that marketing authorisation of EVKEEZA should be maintained. |
| IB/0009             | B.II.h.1.b.2 - Update to the Adventitious Agents Safety Evaluation information - Replacement of obsolete studies related to manufacturing steps and adventitious agents already reported in the dossier - without modifications of risk assessment                                         | 15/06/2023   | n/a        |                       |                                                                                                                                                                                                                                                                  |
| PSUSA/10945 /202208 | Periodic Safety Update EU Single assessment - evinacumab                                                                                                                                                                                                                                   | 16/03/2023   | n/a        |                       | PRAC Recommendation - maintenance                                                                                                                                                                                                                                |
| IAIN/0006/G         | This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                      | 12/10/2022   | 05/10/2023 | SmPC, Annex II and PL |                                                                                                                                                                                                                                                                  |

<div style=\"page-break-after: always\"></div>

|                     | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.5.c - Change to in-process tests or limits applied during the manufacture of the finished product - Deletion of a non-significant in-process test A.6 - Administrative change - Change in ATC Code/ATC Vet Code B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release -   |            |            |                        |                                                                                                                                                                                                                                                                  |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10945 /202202 | Periodic Safety Update EU Single assessment - evinacumab                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 29/09/2022 | n/a        |                        | PRAC Recommendation - maintenance                                                                                                                                                                                                                                |
| S/0005              | 1st annual re-assessment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 15/09/2022 | n/a        |                        | The CHMP, having reviewed the evidence of compliance with the specific obligations and the impact of the data submitted by the MAH on the benefit/risk profile of the medicinal product, concluded that marketing authorisation of EVKEEZA should be maintained. |
| T/0003              | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 31/03/2022 | 13/04/2022 | SmPC, Labelling and PL |                                                                                                                                                                                                                                                                  |

<div style=\"page-break-after: always\"></div>

| IB/0002/G           | This was an application for a group of variations. B.II.f.1.e - Stability of FP - Change to an approved stability protocol B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits   | 11/04/2022   | n/a   |                                   |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|-----------------------------------|
| PSUSA/10945 /202108 | Periodic Safety Update EU Single assessment - evinacumab                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 10/03/2022   | n/a   | PRAC Recommendation - maintenance |